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The aim of this study is to examine the long-term impact (up to 10-yr follow-up) of CMV infection on the allograft and patient outcomes in a large cohort of ϳ600 renal transplant patients with protocol biopsies. Our analysis focuses on allograft function, morphological injury, and the end points of patient and graft survival.
MATERIALS AND METHODS

Patients.
A total of 594 patients with a kidney or a combined kidney/pancreas transplantation between 2001 and 2004 were included in this retrospective analysis. All patients were enrolled in the renal transplant protocol biopsy program as described below. Patient demographics and characteristics are summarized in Table 1 . It is the same patient cohort of our recent study analyzing the impact of CMV infection on acute rejection in renal transplantation (4) .
Induction therapy was given in 88% of all patients (ATG in 6% and IL-2 antibodies in 82%). Maintenance therapy with dual immunosuppression consisted of cyclosporine A and prednisolone in 200 of 594 patients (33.7%); 227 patients (38.2%) received triple immunosuppression with additional mycophenolate mofetil (MMF). In 167 patients (28.1%), alternative regimens, including sirolimus or azathioprine and tacrolimus instead of cyclosporine A, were used. Standard therapy for first-time acute tubulointerstitial rejection Banff grade Ia/Ib with and without a rise in serum creatinine consisted of pulse methylprednisolone, 250 -500 mg intravenously given for 3 days. Additionally, in patients receiving dual immunosuppression with cyclosporine A and prednisolone, MMF was added. Patients with cyclosporine A-containing regimens who experienced a second acute tubulointerstitial rejection episode (ARE) or who had the rejection later than 3 mo posttransplantation were switched to tacrolimus. Patients with borderline rejection were treated like patients with acute tubulointerstitial rejection if baseline creatinine had increased Ͼ25%. Acute vascular rejections were treated with steroid boli (500 mg prednisolone) and a switch from cyclosporine A to tacrolimus. All patients received prophylaxis for Pneumocystis jirovecii with trimethoprim/sulfamethoxazole three times a week for 6 mo. Prophylactic antiviral treatment to prevent CMV infection is described below.
Protocol biopsy program and biopsies. Renal protocol biopsies are regularly performed at the transplant center of the Hannover Medical School (Hannover, Germany) at 6 wk, 3, and 6 mo after kidney or combined kidney/pancreas transplantation (23) . About 45% of patients have additional biopsies to evaluate unexplained allograft dysfunction (clinically indicated biopsy). Demographic, clinical, and routine laboratory data are concomitantly collected for each patient. The data are entered into a customized database (Oracle Enterprises, version 8.0.5). The institutional review board at Hannover Medical School approved the protocol biopsy program, and informed consent was obtained from each patient.
Biopsies were evaluated according to the updated Banff classification assessing grade of interstitial fibrosis/tubular atrophy (IF/TA), vascular, and glomerular lesions (26) . Analysis included a total of 1,483 protocol biopsies (484 biopsies at 6 wk, 517 and 482 biopsies at 3 and 6 mo, respectively).
Definition of CMV infection. CMV viremia and CMV disease were considered as CMV infection. CMV viremia was defined as any detectable virus by quantitative PCR above the threshold of 600 copies/ml or positive antigenemia testing (CMVpp65 antigen Ͼ2 positive cells/400,000 cells) without clinical symptoms (2, 3) . CMV disease included CMV syndrome (flu-like as fever and myalgia) and organ involvement such as hepatitis, gastrointestinal disease, leukopenia/thrombocytopenia, according to the criteria described by Ljungman et al. (16) and Preiksaitis et al. (17) . CMV colitis was assumed when CMV antigenemia was detected and other causes of diarrhea were excluded. Histological evidence of tissue invasion was established only in a few of those cases. Hepatitis was defined as a rise of hepatic transaminases and cholestatic parameters twice the initial values without other known causes. Leukopenia was defined as a leukocyte count Ͻ4 ϫ 10 9 /l, thrombocytopenia Ͻ100 ϫ 10 9 /l, or any significant decrease from baseline values with other causes such as drug effects or infection excluded. Recurrence of CMV infection was defined as any episode occurring Ͼ28 days after the end of a previous infection, in accordance with previous reports (16) . For a description of virological testing and prophylaxis/therapy for CMV infection and/or disease, we refer the reader to our previous publication about this cohort (4) .
Statistical analysis. Continuous data were reported as means with standard deviation. Comparisons of categorical data between groups were performed with Fisher's exact test and the 2 test for two or more samples. Continuous data were tested using a Kruskal-Wallis test and the Mann-Whitney test. Kaplan-Meier survival estimates were used to determine graft and patient survivals between groups applying the log-rank test. Variables associated with CMV were compared between survivors with a functioning graft, patients with graft loss, and deceased patients. Univariate Cox hazard ratios and 95% confidence intervals (CI) with lower and upper limits were calculated for the seven variables that were different with a P value of Ͻ0.1. These variables were used for multivariate Cox regression analyses using backward selection (P ϭ 0.5 to 0.1 to enter as well as to stay in the model). Distributional assumptions for Cox regression using scaled Schoenfeld residuals were examined for each predictor and tested with a global PH-Test. The Cox regression models were validated in the R-Program (rms-Package) using 200 bootstraps at 10 yr. The probability estimates were validated on calibration graphs. Harrells' concordance index, shrinkage, and R2 Nagelkerke were calculated for the Cox models. Statistical significance was assumed for P Ͻ 0.05. PASW-Statistic 22 Software system (SPSS, IBM, Chicago, IL) and R Software [R version 3.1.1, 2014-07-10; Copyright (C) 2014, The R Foundation for Statistical Computing] were used to perform the calculations. Statistical significance was assumed for P Ͻ 0.05.
RESULTS
Incidence of CMV infection.
A proportion of 153 of the 594 patients (26%) developed CMV infection within 12 mo posttransplantation. Twenty-eight patients were diagnosed with CMV before the protocol biopsy at 6 wk (18%). Most of the infections occurred between 6 wk and 6 mo posttransplantation (n ϭ 117; 76%) and a few between months 6 and 12 (n ϭ 8; 5%). After the first year, no new CMV infections were detected.
Outcome by allograft function. Allograft function was assessed by the estimated glomerular filtration rate (eGFR) according to the Cockroft and Gault formula (1) . The best eGFR achieved within the first 6 wk after transplantation was only numerically lower in patients with CMV (57 Ϯ 23 vs. 61 Ϯ 23 ml/min; P ϭ 0.083). Over the time period of up to 10 yr, the annual loss of GFR was greater in patients with CMV compared with patients without CMV (median: 3.6 vs. 2.4 ml·min Ϫ1 ·yr Ϫ1 ; P ϭ 0.017). The loss of GFR was comparable among the subgroups of patients who developed CMV infection within the first 6 wk after transplantation, between 6 wk and 6 mo, and after 6-mo posttransplantation (medians: 3.6 vs. 3.3 vs. 3.5 ml·min Ϫ1 ·yr Ϫ1 ). Outcome by histology. Due to the lack of "null" biopsies at the day of transplantation, the 6-wk biopsies might reflect effects of CMV on the graft in cases in which patients had CMV within the first 6 wk posttransplantation. Therefore, chronic changes were analyzed separately in patients with CMV infection before the protocol biopsy at 6 wk and in patients with CMV infection between the protocol biopsies at 6 wk and 6 mo.
In the 6-wk biopsies, the prevalence of Banff IF/TA grades Ͼ0 was threefold higher in both groups with CMV infection (13% in the patients with CMV infection before 6 wk; 11.5% in the patients with CMV infection between 6 wk and 6 mo) compared with 3.5% in the control patients without CMV (Fig.  1) . This was statistically different for patients who had CMV infection between 6 wk and 6 mo posttransplantation (P ϭ 0.005).
At 6 mo, the prevalence of IF/TA grades Ͼ0 rose to 55% in patients with CMV infection before 6 wk and to 40.6% in patients with CMV between 6 wk and 6 mo. This was not significantly different from the patients without CMV (34.2%). Only a small proportion of IF/TA grade II was observed among the groups.
In patients who had protocol biopsies available from 6 wk and 6 mo, the increase in IF/TA was examined. Of the 78 patients who developed CMV between 6 wk and 6 mo, 31 (40%) had an increase from 6 wk to 6 mo, compared with 98 (31%) patients without CMV (n ϭ 319). Similarly, of the 18 patients with CMV occurrence before 6 wk, 8 patients (44%) had an increase in IF/TA which was not different from the patients without CMV (P ϭ 0.29).
Chronic vascular and glomerular changes were rarely seen in the protocol biopsies. At 6 wk, chronic vascular lesions were present in four patients (1%) without CMV. At 6 mo, vascular lesions were present in 10 patients (2.7%) without CMV and in 2 patients (2%) with CMV between 6 wk and 6 mo. Chronic glomerular lesions were only found at 6 mo in 3 patients (0.8%) without CMV.
Outcome by patient and graft survival. Data on patient and graft survival and function were available up to 10 yr posttransplantation. Loss to follow-up was negligible (7 patients in the patient group without CMV). A total of 82 deaths (27 in patients with CMV infection and 55 in patients without) were observed. Death in patients with and without CMV infection was related to cardiovascular causes in 12 vs. 17%, to malignancies in 15 vs. 15%, and to infection in 39 vs. 20%. Cause of death was unknown in 31% in patients with and in 39% in patients without CMV infection. Terminal graft failure occurred in 27 patients with CMV infection and in 50 patients without CMV. Survival analyses are shown in Fig. 2 , revealing significantly reduced patient and graft survival (P ϭ 0.008) and reduced graft survival censored for death in patients with CMV (P ϭ 0.032).
Factors in patient and graft survival. In our previous analysis (4), we examined a large number of pretransplantation recipient data and variables from the donor and the perioperative period for patients with and without CMV posttransplantation. The univariate comparisons showed an association of CMV with higher recipient and donor age, pretransplantation pregnancies, presence of coronary heart disease and history of myocardial infarction, donor (D)/recipient (R) CMV IgG serostatus combinations (Dϩ/RϪ, Dϩ/Rϩ, DϪ/Rϩ), need of posttransplantation dialysis, and inferior graft function in the first 6 wk after transplantation. Subsequent logistic regression analysis revealed that CMV serostatus was the strongest factor for CMV infection. Moreover, these results suggested that CMV infection is linked to other factors which are relevant for long-term patient and graft outcome.
In the present study, we compared the factors determined in our first study (4) (listed above) in the groups of survivors with a functioning graft, patients with graft loss, and deceased patients. The results are summarized in Table 2 . Patients with graft loss and death had organs from older donors, a lower graft function within the first 6 wk posttransplantation, a higher frequency of dialysis treatment for delayed graft function, and more frequently a history of coronary heart disease. CMV infection was more prevalent in patients with graft loss (P Ͻ 0.05) whereas the proportion of CMV infection in patients who died was only insignificantly higher (P ϭ 0.08). Recipient age was higher in the group of deceased patients only. Initial maintenance immunosuppression was not significantly different between patients with and without CMV infection (Table 3) .
For variables with a P value of Ͻ0.1, univariate Cox hazard ratios were calculated and multivariate Cox models were built for graft loss and patient death (Table 4) . Recipient age and need of posttransplantation dialysis were identified as significant variables for death. Coronary heart disease, donor age, and inferior graft function in early posttransplantation were identified as significant variables for graft loss. CMV infection or viremia was not a significant factor in these multivariate models.
Causes of graft failure. It has been suggested that CMV causes specific chronic vascular and tubulointerstitial lesions that can lead to terminal graft failure. In our patients, systematic biopsies were not available in the long-term posttransplantation course to test this hypothesis, and analysis of the available late biopsies from some patients alone would have resulted in biased conclusions. Therefore, to better understand the increased rate of graft failure in patients with CMV, we deduced the most likely cause of graft failure individually for each patient, taking into account the clinical course, laboratory findings, and any available biopsies. In many patients, terminal graft failure was not attributable to a single cause (28 of the 49 patients without CMV, 22 of the 27 patients with CMV). In these patients, a secondary cause was defined on clinical grounds. Causes were similarly distributed in both groups; however, there was a trend in patients with CMV toward more graft failures associated with an inferior graft from the beginning (Fig. 3, A and B) . (5, 7, 9) . CMV infection has been associated with acute and chronic rejection, chronic allograft changes, and decreased graft and patient survival; however, this remains controversial (6, 11, 20, 29) . A general obstacle in the assessment of the chronic effects of CMV is the high heterogeneity of the published studies. Studies differ in CMV screening protocols and drugs used for antiviral treatment. Different regimens for antiviral treatment have been examined, including treatment of CMV disease only, preemptive, and prophylactic treatment with variable durations of the prophylaxis (6, 12, 14, 21, 22, 25, 28) .
In our previous analysis, we examined the short-term graft outcome of patients with CMV and the possible relationship to acute rejection. We observed a higher prevalence of coexisting conditions like high donor age and delayed graft function in patients with CMV, thus explaining the inferior graft function during the first 2 yr after transplantation in these patients (4). In the current study, we utilized the same cohort but focused on the relationship of CMV to chronic lesions in protocol biopsies, and to the graft function, graft, and patient survival in the long term of up to 10 yr posttransplantation.
Renal function within the first 6 wk after transplantation in patients with CMV viremia or disease was only insignificantly lower than in patients without CMV, yet the annual loss of GFR was greater (by 50%) in patients with CMV in our study. This translated into a lower graft survival in patients with CMV.
Only a few studies examined outcome on graft function over time. One study of Ͼ2,500 patients examined the relationship between CMV serostatus and graft function over 5 yr and did not find differences in the loss of GFR and in graft survival (15) . However, this study did not examine CMV viremia or disease, which might not allow direct comparison to our study. In a smaller study of ϳ95 patients (DϩRϪ, DϩRϩ, DϪRϩ) of which 48 patients received prophylactic and 47 preemptive treatment, no difference in annual loss of GFR and graft loss up to 5 yr was observed (28) . A third study of 104 patients with a follow-up to 7 yr (only high-risk group treated; DϩRϪ) confirmed these findings (22) . The different design with shorter follow-up and smaller patient cohorts of the last two studies (22, 28) could account for the different results. Interestingly, in the era before prophylaxis and preemptive antiviral CMV treatment, Sagedahl et al. (21) demonstrated in a cohort of nearly 500 patients with a follow-up to 5.5 yr that neither CMV infection nor disease was an independent risk factor for uncen- sored graft loss or decrease in graft function. In line with our findings, a more recent, but small study of a pediatric cohort of 55 children found an association between CMV viremia and decrease in graft function by 28% at 2 yr (27) . The inconsistent results of the studies listed above demonstrate the need to study larger cohorts with long-term follow-up as it was possible in our 10-yr follow-up study. However, differences in patient population and study design may be the most likely possible explanation for these inconsistent results.
Other studies focused merely on graft survival. The UK Renal Registry study from Johnson et al. (11) looked at CMV serostatus of Ͼ8,000 adult and pediatric patients who underwent transplantation between 2000 and 2007. CMV mismatch did not affect graft survival up to 8 yr. Yet, CMV viremia and disease were not analyzed in this study. In contrast, another large study with 1,279 patients reported an increased risk for allograft loss for patients whose donor had a positive CMV serology status (6) . This was independent of episodes of viremia. However, the detrimental effect of CMV positivity was restricted to patients with a full human leukocyte antigen (HLA) mismatch and patients with decreased numbers of CD8ϩ cells. A more recent prospective study of 606 renal transplant recipients with preemptive treatment revealed that latent CMV infection, defined as seropositive or seroconverted, was a significant risk factor for graft failure up to 7 yr (29) . Again, these studies differ in design and direct comparison is difficult, and consideration of other clinical factors besides CMV serostatus, CMV infection, and disease is often lacking.
Only a few studies have analyzed the impact of CMV infection on histology in human renal allografts (8, 19, 28) . Animal data suggest that CMV infection is related to allograft loss (25) . In chronic allograft nephropathy models, CMV infection was associated with an induction of growth factors and collagen synthesis (10, 13) . In this regard, Helantera et al. (8) detected increased urinary transforming growth factor-␤ in 13 renal transplant recipients during CMV infection, however, without clear-cut time-relationships to interstitial fibrosis and tubular atrophy development. Reischig et al. (19) examined 50 late renal graft biopsies from patients with preemptive or prophylactic CMV treatment. Prophylactic treatment, with more cases of late onset viremia, was associated with increased expression of fibrosis genes whereas IF/TA did not differ from the patients with preemptive therapy. Another prospective study looked at ϳ100 patients with either preemptive or prophylactic treatment and found no differences in IF/TA between these two groups (28) . All CMV serogroups except DϪ/RϪ were included, in this study but viremia was not analyzed (28) .
In our cohort of ϳ600 patients, we were able to compare the evolution of IF/TA in serial biopsies at 6 wk and 6 mo posttransplantation in a systematic fashion. One important finding from this study is that recipients with CMV had a higher prevalence of IF/TA even before CMV infection. This suggests that graft damage is rather related to donor factors like age or preexisting renal injury. This is supported by the fact that the proportion of IF/TA-positive biopsies increased similarly in patients with and without CMV at 6 mo. Biopsies at later time points might have been helpful to delineate the course of morphological changes in patients with and without CMV but were only available in some patients. To better understand the increased rate of graft failure in patients with CMV, we determined the most likely cause(s) for graft failure by analyzing the clinical course, laboratory findings, and any available biopsies. This approach could be criticized for its subjectivity. However, from a clinical perspective evaluation of allograft deterioration should not be based only on nonspecific or specific biopsy lesions, without taking in account the clinical course. In fact, we discovered that causes for graft loss were very heterogeneous but similarly distributed in patients with and without CMV. There was a slight preponderance of marginal graft function from the beginning in patients with CMV. These results imply that there is no single, CMV-related lesion as cause for the graft failures in the CMV group.
On the other hand, our previous analysis (4) suggested that CMV infection coincides with other factors which are relevant for long-term patient and graft outcome. Our multivariate analyses indicate that increased graft loss was explained by higher donor age and inferior function early posttransplantation whereas CMV viremia or disease was not a significant factor. Also, there were no differences in the initial immunosuppressive therapy between patients with and without CMV, which might explain the occurrence of CMV and the observed inferior outcome in the patients with CMV. This is in line with other studies which revealed donor age, acute rejection, HLA mismatches, preimmunization of the recipient, and diabetes mellitus as significant factors for graft survival but could not establish an independent effect of CMV viremia or disease, even in patients without prophylactic or preemptive antiviral treatments (21, 22) . Similarly, CMV viremia or disease was not retained as a significant factor for death in the multivariate analysis of our study; only higher patient age and delayed graft function remained as significant factors. This is in accordance with results from San-Juan et al. (22) , who identified recipient age (and pretransplant diabetes) as significant factors for mortality, whereas CMV viremia or disease had no impact. In contrast, in the era without antiviral prophylaxis or preemptive therapy, CMV disease and recipient age were shown to have a significant effect on mortality (21) . Larger studies using data from the UK registry (11) and from ANZData (15) examined the effect of CMV serostatus. Again, recipient age was the major factor for mortality, and no association between CMV and mortality was observed. There are possible limitations to this study. The study design is retrospective in nature and is not able to establish causeeffect relationships. Nevertheless, we utilize a large cohort of patients with a 10-yr follow-up that can outweigh the deficits a retrospective study carries. In addition, we were able to analyze a large cohort of protocol biopsies, done in a systematic fashion, which allowed us to analyze the impact of CMV on morphology and function of the renal allograft. We acknowledge that even with this large sample size, failure to detect a small effect of CMV that is present (in statistical terms, a type II error) cannot be excluded.
Another limitation is the fact that we do not have null biopsies and serial biopsies later than 6 mo; nevertheless, we have longer follow-up data for function and clinical data which may balance this deficit.
In conclusion, patients with CMV posttransplantation show more chronic renal allograft changes early on, even before CMV infection. In the current era of prophylaxis/preemptive antiviral treatment, according to current guidelines other factors like higher donor and patient age appear to be more important for long-term graft and patient outcome.
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